(Sharecast News) - AstraZeneca shares rallied on Monday after it emerged that US President Donald Trump is considering fast-tracking an experimental Covid-19 vaccine being developed by the pharmaceuticals giant and Oxford University.
The Financial Times cited three people briefed on the plan as saying that one option being considered to speed up the availability of a vaccine involves the US Food and Drug Administration awarding 'emergency use authorisation' (EUA) in October, based on the results from a relatively small UK study if it is successful.
The AstraZeneca study falls short of the number of participants required for FDA approval. The company has enrolled 10,000 volunteers, whereas the US government's scientific agencies have said a vaccine would need to be studied in 30,000 people to pass the threshold for authorisation.
In July, AstraZeneca said that the vaccine had produced a "strong immune response" in Phase I/II trial results.
At 1155 BST, the shares were up 3.9% at 8,762.54p.
By Allison Martell and Euan RochaMay 7 (Reuters) - To fight the pandemic at home, the United States gave its own vaccine manufacturers priority access to American-made materials needed to make the shots.As a result, the U.S. government laid claim n...